ACIPHEX

This brand name is authorized in United States, South Africa

Active ingredients

The drug ACIPHEX contains one active pharmaceutical ingredient (API):

UNII 3L36P16U4R - RABEPRAZOLE SODIUM

Rabeprazole belongs to the class of anti-secretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonist properties, but suppress gastric acid secretion by the specific inhibition of the H+/K+ -ATPase enzyme (the acid or proton pump).

Read about Rabeprazole

Medication package inserts

Below package inserts are available for further reading:

Title
Information Source
Document Type
 
ACIPHEX SPRINKLE Delayed-release capsule
FDA, National Drug Code (US)
MPI, US: SPL/PLR
ACIPHEX Delayed-release tablet
FDA, National Drug Code (US)
MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
A02BC04
Rabeprazole
A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BC Proton pump inhibitors
Discover more medicines within A02BC04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
US
FDA, National Drug Code
Identifier(s): 23594-205, 23594-210, 62856-243
ZA
Health Products Regulatory Authority
Identifier(s): A39/11.4.3/0468, A39/11.4.3/0469

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈